Ascelia Pharma AB (publ) (ACE) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Ascelia Pharma Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.892 -- 00:00:06.759 Thank you and welcome everyone to the webcast for Acelia Pharma's Q2 report for 2025. 00:00:06.759 -- 00:00:11.462 On this call we will be making a number of forward-looking statements. 00:00:11.625 -- 00:00:15.729 On today's call we will start with recent key events and then head into our portfolio 00:00:15.729 -- 00:00:17.131 update 00:00:17.131 -- 00:00:20.415 before we move to financials and priorities ahead. 00:00:20.415 -- 00:00:24.698 After the presentation we will open up for questions as usual. 00:00:25.664 -- 00:00:30.250 At the Senior Pharma, we identify, develop, and commercialize novel drugs that address 00:00:30.250 -- 00:00:33.374 unmet medical needs within rare cancer conditions. 00:00:33.374 -- 00:00:38.400 We have two drugs in our pipeline. OrbeGlance is in the registration phase, as we have 00:00:38.400 -- 00:00:43.446 successfully completed the pivotal phase three clinical study known as SPARQL, and 00:00:43.446 -- 00:00:48.232 we're preparing the NDA submission, which will be submitted soon. 00:00:48.232 -- 00:00:52.678 OrbeGlance has orphan drug designation from the FDA and is targeting an addressable market 00:00:52.678 -- 00:00:55.685 opportunity of $800 million. 00:00:55.685 -- 00:00:59.910 Oncoral is ready to start phase two clinical development for the treatment of gastric 00:00:59.910 -- 00:01:06.077 cancer based on encouraging results in phase one and a high level of unmet medical need. 00:01:06.077 -- 00:01:11.240 Our company is headquartered in Malmö in Sweden and we're listed on Nasdex.com. 00:01:12.244 -- 00:01:17.490 The second quarter of 2025 was focused on finalizing the Oreglands NDA submission 00:01:17.490 -- 00:01:21.855 following our meeting with the FDA in Q1. 00:01:21.855 -- 00:01:24.878 I'...